Ftse Mib
34.264,81
-0,29%
DAX
18.088,70
-0,30%
S&P 500
5.066,43
-0,08%
NASDAQ Composite
15.738,90
0,27%
Bitcoin
64.671,96
-2,62%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistente personale
Home Investire Azioni U.S.A. NASDAQ NeuroMetrix Inc (NURO) NeuroMetrix Inc (NURO) Notizie

NeuroMetrix Inc

NURO
4,40
-0,039 (-0,88%)
Ultimo aggiornamento: 19:55:54
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
19/4/202414:00GLOBENeuroMetrix Announces Steps Taken to Enhance Shareholder..
14/3/202414:00GLOBENeuroMetrix Announces Publication of Study Demonstrating..
13/3/202414:00GLOBENeuroMetrix announces that over 2000 patients with..
06/3/202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202423:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202422:12EDGAR2Form SC 13D/A - General statement of acquisition of..
01/3/202423:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202422:45EDGAR2Form 8-K/A - Current report: [Amend]
27/2/202422:00EDGAR2Form SC 13D - General statement of acquisition of beneficial..
26/2/202423:41EDGAR2Form SC 13D - General statement of acquisition of beneficial..
22/2/202413:15EDGAR2Form 8-K - Current report
22/2/202413:00GLOBENeuroMetrix Reports Q4 and Full Year 2023 Business..
20/2/202420:49EDGAR2Form SCHEDULE 13G - Statement of acquisition of beneficial..
15/2/202415:00GLOBENeuroMetrix, Inc. Announces Date for Fourth Quarter and Full..
13/2/202415:00GLOBENeuroMetrix Announces Review of Strategic Options to Promote..
12/12/202315:00GLOBENeuroMetrix Reports Encouraging Results from Pilot Clinical..
05/12/202315:00GLOBENeuroMetrix Announces Peer-Reviewed Publication of Phase 2..
20/11/202315:33EDGAR2Form 8-K - Current report
20/11/202315:00GLOBENeuroMetrix Announces One-for-Eight Reverse Stock Split
26/10/202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26/10/202313:11EDGAR2Form 8-K - Current report
26/10/202313:00GLOBENeuroMetrix Reports Q3 2023 Business Highlights
23/10/202317:13GLOBENeuroMetrix, Inc. Announces Date for Third Quarter 2023..
20/10/202320:59EDGAR2Form 8-K - Current report
02/10/202315:00GLOBENeuroMetrix and the National Fibromyalgia Association to..
11/9/202313:59EDGAR2Form DEF 14A - Other definitive proxy statements
11/8/202323:11EDGAR2Form 8-K - Current report
05/8/202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/8/202300:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/8/202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/8/202323:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202322:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/7/202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/7/202313:24EDGAR2Form 8-K - Current report
27/7/202313:00GLOBENeuroMetrix Reports Q2 2023 Business Highlights
20/7/202319:00GLOBENeuroMetrix, Inc. Announces Date for Second Quarter 2023..
11/7/202315:00GLOBENeuroMetrix Announces Sales Force Expansion for Quell..
28/6/202315:00GLOBERecent Publications Demonstrate Utility of DPNCheck® for..
07/6/202315:00GLOBEDiabetic Peripheral Neuropathy Screening That Includes..
31/5/202315:00GLOBEQuell® Demonstrates Encouraging Clinical Trial Results in..
03/5/202313:00GLOBENeuroMetrix Reports Q1 2023 Financial Results
28/4/202315:21GLOBENeuroMetrix, Inc. Announces Date for First Quarter 2023..
Apertura: 4,44 Min: 4,3446 Max: 4,44
Chiusura: 4,439

La tua Cronologia

NASDAQ
NURO
NeuroMetrix
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network